Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Formally described in the 1960s, melanoma of unknown primary (MUP) is characterized by the finding of metastatic melanoma within the lymph nodes, subcutaneous tissues, and other distant sites without an evident primary lesion. The most likely hypothesis of its etiology is an immune-mediated regression of the primary after metastasis has occurred.In addition, patients with MUP appear to have equivalent or better outcomes compared with patients with known primaries of a similar stage. K E Y W O R D S malignant melanoma, melanoma occult primary, melanoma regression, unknown primary 1 | INTRODUCTION Melanoma incidence has increased steadily over the last three decades. Over 90 000 new cases are estimated to be diagnosed in the year 2018 in the United States. 1 The vast majority of cases are cutaneous melanoma, but melanoma can also occur in extracutaneous locations, such as the eyes or mucous membranes. 2 Although more than 90% of cases are comprised of melanomas with a known primary site (MKP), occasionally it is discovered first as a secondary deposit within lymph nodes, subcutaneous tissues, or other organs without a clearly evident site of origin. The first diagnosis of melanoma of unknown primary (MUP) dates back to 1917. 3 Pack et al 3 described a series of 1,190 patients treated at Memorial Hospital between 1917 and 1950, of which 29 (2.4%) patients were classified as having an occult primary. Compared with other patients with melanoma, patients diagnosed with MUP were initially reported to have especially poor outcomes. While the overall 5-year recurrence-free survival was 21.4%, only one patient with MUP was cured. The authors wrote that "the patient defies all laws and expectations by continuing to live" 14 years after initial axillary dissection for lymph node metastasis. Das Gupta 4 formally described the entity of MUP in 1963. His proposed diagnostic criteria excluded patients who had any of the following: a history of orbital exenteration or enucleation; a history of excision or removal of any mole, birthmark, freckle, chronic paronychia, or skin blemish; scar in the skin drained by the nodal basin containing metastatic melanoma; and an incomplete physical examination, which also included ophthalmoscopy and examination of the anus and genitalia. 2 | DIAGNOSTIC CRITERIA Few studies use the full diagnostic criteria set forth by Das Gupta to define MUP. 5-10 In a systematic review, Kamposioras et al 11 reported that only 16% of published peer-reviewed studies of MUP used the original Das Gupta criteria to define cases of unknown primaries. The majority of studies make the diagnosis of MUP based on history, physical examination, pathology, and imaging, resulting in heterogeneity and variations in how MUP is defined. Studies typically vary in the completeness of physical examination required and the exclusion of patients with previously existing skin lesions. For example, Wong et al and Katz et al 12,13 defined patients as having MUP only if they had a documented thorough skin examination and did not have an...
Formally described in the 1960s, melanoma of unknown primary (MUP) is characterized by the finding of metastatic melanoma within the lymph nodes, subcutaneous tissues, and other distant sites without an evident primary lesion. The most likely hypothesis of its etiology is an immune-mediated regression of the primary after metastasis has occurred.In addition, patients with MUP appear to have equivalent or better outcomes compared with patients with known primaries of a similar stage. K E Y W O R D S malignant melanoma, melanoma occult primary, melanoma regression, unknown primary 1 | INTRODUCTION Melanoma incidence has increased steadily over the last three decades. Over 90 000 new cases are estimated to be diagnosed in the year 2018 in the United States. 1 The vast majority of cases are cutaneous melanoma, but melanoma can also occur in extracutaneous locations, such as the eyes or mucous membranes. 2 Although more than 90% of cases are comprised of melanomas with a known primary site (MKP), occasionally it is discovered first as a secondary deposit within lymph nodes, subcutaneous tissues, or other organs without a clearly evident site of origin. The first diagnosis of melanoma of unknown primary (MUP) dates back to 1917. 3 Pack et al 3 described a series of 1,190 patients treated at Memorial Hospital between 1917 and 1950, of which 29 (2.4%) patients were classified as having an occult primary. Compared with other patients with melanoma, patients diagnosed with MUP were initially reported to have especially poor outcomes. While the overall 5-year recurrence-free survival was 21.4%, only one patient with MUP was cured. The authors wrote that "the patient defies all laws and expectations by continuing to live" 14 years after initial axillary dissection for lymph node metastasis. Das Gupta 4 formally described the entity of MUP in 1963. His proposed diagnostic criteria excluded patients who had any of the following: a history of orbital exenteration or enucleation; a history of excision or removal of any mole, birthmark, freckle, chronic paronychia, or skin blemish; scar in the skin drained by the nodal basin containing metastatic melanoma; and an incomplete physical examination, which also included ophthalmoscopy and examination of the anus and genitalia. 2 | DIAGNOSTIC CRITERIA Few studies use the full diagnostic criteria set forth by Das Gupta to define MUP. 5-10 In a systematic review, Kamposioras et al 11 reported that only 16% of published peer-reviewed studies of MUP used the original Das Gupta criteria to define cases of unknown primaries. The majority of studies make the diagnosis of MUP based on history, physical examination, pathology, and imaging, resulting in heterogeneity and variations in how MUP is defined. Studies typically vary in the completeness of physical examination required and the exclusion of patients with previously existing skin lesions. For example, Wong et al and Katz et al 12,13 defined patients as having MUP only if they had a documented thorough skin examination and did not have an...
Fifty-six cases of this uncommon neoplastic manifestation are presented. These cases represent 0.065% of 86,589 new cases of malignant disease seen at The Princess Margaret Hospital from 1968 to 1982. There were 29 men and 27 women. The median age at presentation was 58 years. Three major groups were identified: inguinal disease, 24 cases; unilateral inguinal plus iliac disease, 16 cases; local plus systemic disease, 16 cases. Pathologic subtypes were anaplastic, 24; squamous, 11; adenocarcinoma, nine; melanoma, nine; and others, three. Survival at 5 years for all patients was 27%. Among 40 patients who presented with inguinal and inguinal plus iliac disease, survival was 37.5% at 5 years. Initial treatment following biopsy was radiation in 35, lymph node dissection in eight, and chemotherapy in four. Excisional biopsy only was performed in nine cases. There were no treatment-related deaths. The findings observed in this study, in which radiation therapy was employed as initial management in the majority of cases, suggests that radiation therapy is a valid alternative to surgery in the management of this disease.
Sixty‐four patients with unknown primary melanoma were identified among 1045 new patients with melanoma (6%) seen during an 11‐year period. Their mean age was 44.5 years (median age, 42.7 years). Of these, 39 (59%) were men, and 25 (38%) were women. In 34, only one site was involved. Common single sites were the axilla (29%), groin (24%), and neck (32%). Most of the melanomas (88%) were melanotic. Patients with localized melanoma surgically treated (n = 34) had a median survival of 53 months, and a 5‐year survival rate of 45%. The respective rates for disseminated melanoma were 7 months and 10% (P = 0.00001). Localized, unknown primary melanoma should be treated with radical excision because a substantial proportion of patients so treated survive 5 years. Cancer 68:2579–2581, 1991.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.